⌕
Thermo Fisher Scientific · TMO · NYSE
Tenet 42 · Weak
Compare
$686.79−0.66%At closeTenet 42 · Weak
$686.79−4.54 (−0.66%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$686.00−0.79 (−0.12%)
After hours: Nov 17, 2026, 6:58 PM ET

Thermo Fisher Scientific (TMO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~3.2%/yr (FY21→FY25), net margin 15.0%, and free cash flow (~$6.3B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▲3.9%
44.6
FY21→FY25CAGR +3.2%/yr
Net income ($B)▲5.8%
6.7
FY21→FY25CAGR −3.5%/yr
Free cash flow ($B)▼13.4%
6.3
FY21→FY25CAGR −1.9%/yr
Diluted EPS▲7.3%
17.74
buyback-liftedCAGR −2.3%/yr
What the receipts whisper · what a headline number hides
Share count
−4.8%

397.0mn → 378.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$1.5B

steady at 3.4% of revenue (+8.9% YoY).

Returns vs FCF
58%

$3.6B returned vs $6.3B of FCF in FY25. Buybacks + dividends covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)44.6Revenue−26.3COGS18.2Gross profit−1.4R&D−8.7SG&A7.7Op income−1.0Tax & other6.7Net income

15¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY21FY25

Over this window: gross 50.1% → 40.9%. Net margin 15.0% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
47,351.044,556.042,879.042,857.044,915.039,211.0▲3.9%+3.2%
Cost of revenue
27,897.026,318.025,177.025,757.025,944.019,573.0▲4.5%+7.7%
Gross profit
19,454.018,238.017,702.017,100.018,971.019,638.0▲3.0%−1.8%
Research & development
1,405.01,397.01,390.01,337.01,471.01,406.0▲0.5%−0.2%
Selling, general & admin
9,187.08,732.08,595.08,445.08,993.08,007.0▲1.6%+2.2%
Total operating expenses
10,985.010,491.010,364.010,241.010,578.09,610.0▲1.2%+2.2%
Operating incomefeeds ROC rank
8,468.07,746.07,337.06,859.08,393.010,028.0▲5.6%−6.3%
Other income, net
−569.0−438.0−300.0−561.0−558.0−1,187.0——
Pretax income
7,899.07,308.07,037.06,298.07,835.08,841.0▲3.9%−4.6%
Income tax
742.0547.0657.0284.0703.01,109.0▼16.7%−16.2%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
7,073.06,704.06,335.05,995.06,950.07,725.0▲5.8%−3.5%
Per share
Diluted EPSbuyback-sensitive
18.9617.7416.5315.4517.6319.46▲7.3%−2.3%
Diluted shares (mn)
371.00378.00383.00388.00394.00397.00▼1.3%−1.2%
Margins
Gross margin22nd pct in Healthcare
41.1%40.9%41.3%39.9%42.2%50.1%▼0.4pp−9.2pp
Operating margin
17.9%17.4%17.1%16.0%18.7%25.6%▲0.3pp−8.2pp
Net margin78th pct in Healthcare
14.9%15.0%14.8%14.0%15.5%19.7%▲0.3pp−4.7pp
† TTM = trailing four quarters through 2026-09-26.
FY07 – FY20 · 14 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Thermo Fisher Scientific's revenue last fiscal year?

Thermo Fisher Scientific reported revenue of $44.6B in fiscal 2025, up 3.9% from fiscal 2024.

What was Thermo Fisher Scientific's net income?

Thermo Fisher Scientific reported net income of $6.7B in fiscal 2025, a net margin of 15.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.